Posted by Michael Wonder on 09 Nov 2021
ICER releases draft evidence report on tirzepatide for type 2 diabetes mellitus
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review today released a draft evidence report assessing the comparative clinical effectiveness and value of tirzepatide (Eli Lilly) for the treatment of type 2 diabetes.
